IPRC has acquired two of the newest Triple Quad mass detectors of AB SCIEX. The two “state of the art”, top of line Triple Quad 6500+ detectors are intended to increase the productivity of IPRC’s Phase I clinical trials unit while enabling compliance with current regulatory requirements. This major investment in LCMSMS, added to the already available AB SCIEX and Waters Triple Quad mass detectors, is anticipated will enable meeting the continuous increasing demands of research and development teams all over the world, and will enable support of the development programs of drugs, e.g., inhalers, that require determination of infinitesimal concentrations in biofluids.